Jazz Pharmaceuticals plc 4

EVP Robert Iannone had 3,764 Jazz Pharmaceuticals ordinary shares withheld for taxes upon RSU vesting, leaving him with 85,107 shares owned.

On June 30, 2026, Robert Iannone, EVP, Global Head of R&D & CMO of Jazz Pharmaceuticals plc, had 3,764 ordinary shares withheld by the company at an implied price of $237.72 per share (approximately $895,000 in value) solely to satisfy tax obligations arising from the vesting of previously granted restricted stock units, leaving him with ownership of 85,107 ordinary shares after the transaction.

Filing Facts

CIK

1232524

Ticker

JAZZ

Form

4

Source Type

sec

Accession

0001737329-26-000010

Alert Tier

5